New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine

Immunological Reviews

Volumn 263, Issue 1, 2015, Pages 36-49

  Moen, Erika L ^a   Mariani, Christopher J ^a   Zullow, Hayley ^a   Jeff Eke, Meselle ^a   Litwin, Edward ^a   Nikitas, John N ^a   Godley, Lucy A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

5 hydroxymethylcytosine; 5 methylcytosine; Epigenetics; Transcriptional regulation

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; ASCORBIC ACID; AZACITIDINE; BETAINE; CYANOCOBALAMIN; CYTOSINE; DECITABINE; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; FOLIC ACID; METHIONINE; MICRORNA; TRANSCRIPTION FACTOR; UNTRANSLATED RNA; 5-HYDROXYMETHYLCYTOSINE;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BINDING SITE; BIOLOGICAL FUNCTIONS; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; DIET SUPPLEMENTATION; DIETARY INTAKE; DNA METHYLATION; DRUG EFFICACY; EMBRYONIC STEM CELL; ENHANCER REGION; EPIGENETICS; EXON; GENE EXPRESSION; GENE INSERTION; GENE STRUCTURE; GENE TARGETING; GENE TECHNOLOGY; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRON; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVERALL SURVIVAL; PHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MODIFICATION; SOMATIC CELL; TRANSCRIPTION INITIATION SITE; ANALOGS AND DERIVATIVES; ANIMAL; DIET; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; STRUCTURE ACTIVITY RELATION;

5-METHYLCYTOSINE; ANIMALS; ASCORBIC ACID; CYTOSINE; DIET; DNA METHYLATION; FOLIC ACID; HEMATOLOGIC NEOPLASMS; HUMANS; MICRORNAS; PROMOTER REGIONS, GENETIC; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 84930330789     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12242     Document Type: Article

References (144)

1. Bartolomei MS, Tilghman SM. Genomic imprinting in mammals. Annu Rev Genet 1997;31:493-525.
2. Panning B, Jaenisch R. RNA and the epigenetic regulation of X chromosome inactivation. Cell 1998;93:305-308.
3. Nagase H, Ghosh S. Epigenetics: differential DNA methylation in mammalian somatic tissues. FEBS J 2008;275:1617-1623.
4. Liang G, et al. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 2002;22:480-491.
5. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010;466:1129-1133.
6. Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930-935.
7. Ito S, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011;333:1300-1303.
8. He YF, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011;333:1303-1307.
9. Jasielec J, Saloura V, Godley LA. The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia 2014;28:1765-1773.
10. Madzo J, Vasanthakumar A, Godley LA. Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. Semin Hematol 2013;50:61-69.
11. Mariani CJ, Madzo J, Moen EL, Yesilkanal A, Godley LA. Alterations of 5-hydroxymethylcytosine in human cancers. Cancers (Basel) 2013;5:786-814.
12. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013;121:3563-3572.
13. Challen GA, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012;44:23-31.
14. Thol F, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011;29:2889-2896.
15. Yan XJ, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011;43:309-315.
16. Mizuno S, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001;97:1172-1179.
17. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999;59:3730-3740.
18. Jiang Y, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315-1325.
19. Marcucci G, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012;30:742-750.
20. Yamashita Y, et al. Array-based genomic resequencing of human leukemia. Oncogene 2010;29:3723-3731.
21. Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev 2013;27:243-259.
22. Kantarjian HM, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:2670-2677.
23. Fenaux P, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
24. Silverman LR, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
25. Kantarjian H, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-1803.
26. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006;20:1-13.
27. Koh KP, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011;8:200-213.
28. Langlois T, et al. TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells. Stem Cells 2014;32:2084-2097.
29. Gu TP, et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011;477:606-610.
30. Iqbal K, Jin SG, Pfeifer GP, Szabó PE. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc Natl Acad Sci USA 2011;108:3642-3647.
31. Wossidlo M, et al. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat Commun 2011;2:241.
32. Delhommeau F, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-2301.
33. Chou WC, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011;118:3803-3810.
34. Moran-Crusio K, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011;20:11-24.
35. Quivoron C, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011;20:25-38.
36. Ko M, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA 2011;108:14566-14571.
37. Li Z, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011;118:4509-4518.
38. Shide K, et al. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 2012;26:2216-2223.
39. Dawlaty MM, et al. Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell 2013;24:310-323.
40. Muto T, et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013;210:2627-2639.
41. Marcucci G, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348-2355.
42. Wang F, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013;340:622-626.
43. Stein E, et al. Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies [abstract]. Proc Ann Meeting AACR. San Diego, CA, 2014.
44. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 2006;103:1412-1417.
45. Kelly TK, et al. H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell 2010;39:901-911.
46. Doi A, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009;41:1350-1353.
47. Lock LF, Takagi N, Martin GR. Methylation of the Hprt gene on the inactive X occurs after chromosome inactivation. Cell 1987;48:39-46.
48. Ooi SK, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007;448:714-717.
49. You JS, Kelly TK, De Carvalho DD, Taberlay PC, Liang G, Jones PA. OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes. Proc Natl Acad Sci USA 2011;108:14497-14502.
50. Williams K, et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011;473:343-348.
51. Ficz G, et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011;473:398-402.
52. Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011;145:423-434.
53. Robertson J, Robertson A, Klungland A. The presence of 5-hydroxymethylcytosine at the gene promoter and not in the gene body negatively regulates gene expression. Biochem Biophy Res Commun 2011;411:40-43.
54. Nguyen C, et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 2001;93:1465-1472.
55. Huang Y, Pastor WA, Shen Y, Tahiliani M, Liu DR, Rao A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS ONE 2010;5:e8888.
56. Jin SG, Kadam S, Pfeifer GP. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res 2010;38:e125.
57. Jones PA. The DNA methylation paradox. Trends Genet 1999;15:34-37.
58. Ball MP, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009;27:361-368.
59. Moen EL, et al. Genome-wide variation of Cytosine modifications between European and african populations and the implications for complex traits. Genetics 2013;194:987-996.
60. Hahn MA, Wu X, Li AX, Hahn T, Pfeifer GP. Relationship between gene body DNA methylation and intragenic H3K9me3 and H3K36me3 chromatin marks. PLoS ONE 2011;6:e18844.
61. Chodavarapu RK, et al. Relationship between nucleosome positioning and DNA methylation. Nature 2010;466:388-392.
62. Chen Y, Chen Q, McEachin RC, Cavalcoli JD, Yu X. H2A.B facilitates transcription elongation at methylated CpG loci. Genome Res 2014;24:570-579.
63. Moen EL, Stark AL, Zhang W, Dolan ME, Godley LA. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther 2014;13:1334-1344.
64. Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS ONE 2011;6:e17388.
65. Wu H, et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev 2011;25:679-684.
66. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009;324:929-930.
67. Mellén M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 2012;151:1417-1430.
68. Hahn MA, et al. Dynamics of 5-hydroxymethylcytosine and chromatin marks in Mammalian neurogenesis. Cell Rep 2013;3:291-300.
69. Colquitt BM, Allen WE, Barnea G, Lomvardas S. Alteration of genic 5-hydroxymethylcytosine patterning in olfactory neurons correlates with changes in gene expression and cell identity. Proc Natl Acad Sci USA 2013;110:14682-14687.
70. Madzo J, et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep 2014;6:231-244.
71. Mariani CJ, et al. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep 2014;7:1343-1352.
72. Laurent L, et al. Dynamic changes in the human methylome during differentiation. Genome Res 2010;20:320-331.
73. Shukla S, et al. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 2011;479:74-79.
74. Choi JK. Contrasting chromatin organization of CpG islands and exons in the human genome. Genome Biol 2010;11:R70.
75. Lyko F, Foret S, Kucharski R, Wolf S, Falckenhayn C, Maleszka R. The honey bee epigenomes: differential methylation of brain DNA in queens and workers. PLoS Biol 2010;8:e1000506.
76. Foret S, et al. DNA methylation dynamics, metabolic fluxes, gene splicing, and alternative phenotypes in honey bees. Proc Natl Acad Sci USA 2012;109:4968-4973.
77. Wan J, Oliver VF, Zhu H, Zack DJ, Qian J, Merbs SL. Integrative analysis of tissue-specific methylation and alternative splicing identifies conserved transcription factor binding motifs. Nucleic Acids Res 2013;41:8503-8514.
78. Khare T, et al. 5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. Nat Struct Mol Biol 2012;19:1037-1043.
79. Huang Y, et al. Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc Natl Acad Sci USA 2014;111:1361-1366.
80. Wen L, et al. Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. Genome Biol 2014;15:R49.
81. Kimura K, et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res 2006;16:55-65.
82. Maunakea AK, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010;466:253-257.
83. Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 2010;1799:694-701.
84. Kulis M, Queirós AC, Beekman R, Martín-Subero JI. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta 2013;1829:1161-1174.
85. Lujambio A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008;105:13556-13561.
86. Lujambio A, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67:1424-1429.
87. Toyota M, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008;68:4123-4132.
88. Di Ruscio A, et al. DNMT1-interacting RNAs block gene-specific DNA methylation. Nature 2013;503:371-376.
89. Schmitz KM, Mayer C, Postepska A, Grummt I. Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. Genes Dev 2010;24:2264-2269.
90. Ginno PA, Lott PL, Christensen HC, Korf I, Chédin F. R-loop formation is a distinctive characteristic of unmethylated human CpG island promoters. Mol Cell 2012;45:814-825.
91. Zhao S, et al. MicroRNA-126 regulates DNA methylation in CD4 + T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum 2011;63:1376-1386.
92. Fabbri M, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007;104:15805-15810.
93. Stadler MB, et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 2011;480:490-495.
94. Woodcock DM, Simmons DL, Crowther PJ, Cooper IA, Trainor KJ, Morley AA. Delayed DNA methylation is an integral feature of DNA replication in mammalian cells. Exp Cell Res 1986;166:103-112.
95. Shirane K, et al. Mouse oocyte methylomes at base resolution reveal genome-wide accumulation of non-CpG methylation and role of DNA methyltransferases. PLoS Genet 2013;9:e1003439.
96. Tomizawa S, et al. Dynamic stage-specific changes in imprinted differentially methylated regions during early mammalian development and prevalence of non-CpG methylation in oocytes. Development 2011;138:811-820.
97. Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007;449:248-251.
98. Shah MY, Licht JD. DNMT3A mutations in acute myeloid leukemia. Nat Genet 2011;43:289-290.
99. Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363:2424-2433.
100. Shlyueva D, Stampfel G, Stark A. Transcriptional enhancers: from properties to genome-wide predictions. Nat Rev Genet 2014;15:272-286.
101. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. Science 2002;295:1306-1311.
102. Schaaf CA, et al. Genome-wide control of RNA polymerase II activity by cohesin. PLoS Genet 2013;9:e1003382.
103. Seitan VC, et al. Cohesin-based chromatin interactions enable regulated gene expression within preexisting architectural compartments. Genome Res 2013;23:2066-2077.
104. Merkenschlager M, Odom DT. CTCF and cohesin: linking gene regulatory elements with their targets. Cell 2013;152:1285-1297.
105. DeMare LE, et al. The genomic landscape of cohesin-associated chromatin interactions. Genome Res 2013;23:1224-1234.
106. Faure AJ, et al. Cohesin regulates tissue-specific expression by stabilizing highly occupied cis-regulatory modules. Genome Res 2012;22:2163-2175.
107. Kon A, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013;45:1232-1237.
108. Thol F, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2014;123:914-920.
109. Rocquain J, et al. Alteration of cohesin genes in myeloid diseases. Am J Hematol 2010;85:717-719.
110. Network CGAR. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-2074.
111. Schmidt D, et al. A CTCF-independent role for cohesin in tissue-specific transcription. Genome Res 2010;20:578-588.
112. Wiench M, et al. DNA methylation status predicts cell type-specific enhancer activity. EMBO J 2011;30:3028-3039.
113. Wu H, Zhang Y. Tet1 and 5-hydroxymethylation: a genome-wide view in mouse embryonic stem cells. Cell Cycle 2011;10:2428-2436.
114. Stroud H, Feng S, Morey Kinney S, Pradhan S, Jacobsen SE. 5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol 2011;12:R54.
115. Gan H, et al. Dynamics of 5-hydroxymethylcytosine during mouse spermatogenesis. Nat Commun 2013;4:1995.
116. Feldmann A, Ivanek R, Murr R, Gaidatzis D, Burger L, Schübeler D. Transcription factor occupancy can mediate active turnover of DNA methylation at regulatory regions. PLoS Genet 2013;9:e1003994.
117. Sérandour AA, et al. Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers. Nucleic Acids Res 2012;40:8255-8265.
118. Szulwach KE, et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci 2011;14:1607-1616.
119. Sun Z, et al. High-resolution enzymatic mapping of genomic 5-hydroxymethylcytosine in mouse embryonic stem cells. Cell Rep 2013;3:567-576.
120. Pastor WA, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 2011;473:394-397.
121. Szulwach KE, et al. Integrating 5-hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells. PLoS Genet 2011;7:e1002154.
122. Okashita N, et al. PRDM14 promotes active DNA demethylation through the ten-eleven translocation (TET)-mediated base excision repair pathway in embryonic stem cells. Development 2014;141:269-280.
123. Costa Y, et al. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature 2013;495:370-374.
124. Song CX, Yi C, He C. Mapping recently identified nucleotide variants in the genome and transcriptome. Nat Biotechnol 2012;30:1107-1116.
125. Yu M, et al. Base-resolution analysis of 5-hydroxymethylcytosine in the Mammalian genome. Cell 2012;149:1368-1380.
126. Song CX, et al. Genome-wide profiling of 5-formylcytosine reveals its roles in epigenetic priming. Cell 2013;153:678-691.
127. Fathi AT, Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol 2012;2012:469592.
128. Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 2014;28:485-496.
129. Stumpel DJ, et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2009;114:5490-5498.
130. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. Adv Nutr 2012;3:21-38.
131. Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J Inherit Metab Dis 2011;34:75-81.
132. Michaud EJ, van Vugt MJ, Bultman SJ, Sweet HO, Davisson MT, Woychik RP. Differential expression of a new dominant agouti allele (Aiapy) is correlated with methylation state and is influenced by parental lineage. Genes Dev 1994;8:1463-1472.
133. Wolff GL, Kodell RL, Moore SR, Cooney CA. Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. FASEB J 1998;12:949-957.
134. Anderson OS, Sant KE, Dolinoy DC. Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J Nutr Biochem 2012;23:853-859.
135. Ly A, Hoyt L, Crowell J, Kim YI. Folate and DNA methylation. Antioxid Redox Signal 2012;17:302-326.
136. Barua S, Kuizon S, Chadman KK, Flory MJ, Brown WT, Junaid MA. Single-base resolution of mouse offspring brain methylome reveals epigenome modifications caused by gestational folic acid. Epigenetics Chromatin 2014;7:3.
137. Rakyan VK, Blewitt ME, Druker R, Preis JI, Whitelaw E. Metastable epialleles in mammals. Trends Genet 2002;18:348-351.
138. Dominguez-Salas P, et al. Maternal nutrition at conception modulates DNA methylation of human metastable epialleles. Nat Commun 2014;5:3746.
139. McDonough MA, Loenarz C, Chowdhury R, Clifton IJ, Schofield CJ. Structural studies on human 2-oxoglutarate dependent oxygenases. Curr Opin Struct Biol 2010;20:659-672.
140. Minor EA, Court BL, Young JI, Wang G. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J Biol Chem 2013;288:13669-13674.
141. Dickson KM, Gustafson CB, Young JI, Züchner S, Wang G. Ascorbate-induced generation of 5-hydroxymethylcytosine is unaffected by varying levels of iron and 2-oxoglutarate. Biochem Biophys Res Commun 2013;439:522-527.
142. Yin R, et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc 2013;135:10396-10403.
143. Blaschke K, et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 2013;500:222-226.
144. Chen J, et al. Vitamin C modulates TET1 function during somatic cell reprogramming. Nat Genet 2013;45:1504-1509.